Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 701–800 of 1,005
Lee, S. H., Bae, S., Kim, K. W., & Lee, Y. M. (2013) · Oncogene · doi:10.1038/onc.2013.76 · Cited by 48
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer
Zhang, Q. H., & Yang, H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00035 · Cited by 47
“REVIEW ARTICLE published: 12 April 2012 doi: 10.3389/fonc.2012.00035 The roles of VHL-dependent ubiquitination in signaling and cancer”
BackgroundMethodInfluentialHypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
Ban, H. S., Uto, Y., Won, M., & Nakamura, H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1146252 · Cited by 44
“ligase and then undergoes ubiquitin/proteasome-dependent degradation.[4,5] A hydroxylation of asparagine 803 residue in C-terminal transactivation domain (CAD) of HIF-1α by factor”
BackgroundRoles of HIF and 2-Oxoglutarate-Dependent Dioxygenases in Controlling Gene Expression in Hypoxia
Frost, J., Frost, M. G., Batie, M., Jiang, H., & Rocha, S. (2021) · Cancers · doi:10.3390/cancers13020350 · Cited by 46
“The detailed mechanism leading to the activation of HIF was unravelled in 2001 [7,8], building on accumulated knowledge of the role of Von Hippel–Lindau Tumor Suppressor (VHL) in this process [9,10].”
BackgroundWilck, N., & Ludwig, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5805 · Cited by 50
“…(18, 83, 84), links the protein to the von Hippel–Lindau tumor suppressor protein (pVHL) (28, 128), a ubiquitin ligase (E3), which ubiquiti-nates HIF-1 a , thereby mediating the extremely rapid pro-teasomal degradation of HIF-1 a in cells under normoxic conditions (28, 92, 143, 160, 178).”
Targeting metabolic pathways for head and neck cancers therapeutics
Yamamoto, M., Inohara, H., & Nakagawa, T. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9691-z · Cited by 45
Molecular switch model for cardiomyocyte proliferation
Hashmi, S., & Ahmad, H. R. (2019) · Cell Regeneration · doi:10.1016/j.cr.2018.11.002 · Cited by 46
“Cells continuously synthesize and degrade HIF-1a protein in normoxic conditions as von HippeleLindau tumor suppressor protein (pVHL) interacts with the a-subunit to target for proteolysis by the ubiquitineproteasome pathway [108,109].”
BackgroundVHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
Lee, C. M., Hickey, M. M., Sanford, C. A., McGuire, C., Cowey, C. L., Simon, M. C., & Rathmell, W. K. (2009) · Oncogene · doi:10.1038/onc.2009.12 · Cited by 46
“pVHL E3 ligase activity targets hypoxia inducible factor (HIF)-a subunits (Iliopoulos et al., 1996; Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000), a family of transcription factor subunits, including HIF-1a and HIF-2a.”
Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells
Alqawi, O., Wang, H. P., Espiritu, M., & Singh, G. (2007) · Free Radical Research · doi:10.1080/10715760701361531 · Cited by 42
Regulation of myogenesis by environmental hypoxia
Beaudry, M., Hidalgo, M., Launay, T., Bello, V., & Darribère, T. (2016) · Journal of Cell Science · doi:10.1242/jcs.188904 · Cited by 48
“protein for ubiquitylation and subsequent destruction by the von Hippel–Lindau (VHL) tumour suppressor (Ohh et al., 2000).”
BackgroundGkotinakou, I.-M., Befani, C., Simos, G., & Liakos, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.225698 · Cited by 43
“In the presence of oxygen, HIF-2α is modified by HIF-specific prolyl4-hydroxylases (PHDs), leading to proteasomal degradation mediated in part by the Von Hippel Lindau tumor suppressor protein (VHL) (Ohh et al., 2000).”
BackgroundHAMANO, K., Esumi, M., Igarashi, H., Chino, K., Mochida, J., ISHIDAand, H., & Okada, K. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(01)69132-8 · Cited by 43
Itoh, T., Namba, T., Fukuda, K., Semenza, G. L., & Hirota, K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03119-2 · Cited by 44
Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Hirota, K. (2015) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x15666150108115553 · Cited by 45
Morais, M., Dias, F., Teixeira, A. L., & Medeiros, R. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.05.028 · Cited by 46
Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling
DeFrates, K. G., Franco, D., Heber‐Katz, E., & Messersmith, P. B. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120646 · Cited by 44
Clark, P. E., & Cookson, M. S. (2008) · Cancer · doi:10.1002/cncr.23645 · Cited by 45
Lam, S., Tipoe, G. L., Liong, E. C., & Fung, M. (2008) · PubMed · doi:10.14670/hh-23.271 · Cited by 45
Yang, L., Jiang, Y., Wu, S.-F., Zhou, M., Wu, Y. L., & Chen, G. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm262 · Cited by 45
“(VHL) tumor suppressor, a part of an E3 ubiquitin ligase [4-6].”
BackgroundOsada, M., Imaoka, S., Sugimoto, T., Hiroi, T., & Funae, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112413200 · Cited by 43
Turcotte, S., Desrosiers, R. R., & Béliveau, R. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00254.2003 · Cited by 49
“von HippelLindau protein (pVHL) is a component of an E3 ubiquitin protein-ligase complex that binds HIF-1 in the ODD (7, 35, 38).”
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)
Ban, H. S., Uto, Y., & Nakamura, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547477 · Cited by 42
“The hydroxylated HIF-1a binds to the von HippelLindau (VHL) tumor suppressor protein, a component of the E3 ubiquitin ligase complex [4-7].”
BackgroundHe, W., Batty-Stuart, S., Lee, J. E., & Ohh, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167244 · Cited by 43
Self-citationRole of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo
Kim, W., Kim, M., Kim, H.-J., Lee, E.-J., Jeong, J., Park, I. H., Jeong, Y. K., & Jang, W. I. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1335440 · Cited by 43
“Under aerobic conditions or in the presence of oxygen, HIF1a is hydroxylated and binds VHL protein, which promotes its ubiquitination and proteasome-mediated degradation [45,46].”
BackgroundClissold, P. M., & Bicknell, R. (2003) · BioEssays · doi:10.1002/bies.10287 · Cited by 42
Zhou, W., Dosey, T. L., Biechele, T. L., Moon, R. T., Horwitz, M. S., & Ruohola‐Baker, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027460 · Cited by 48
“to an ubiquitin E3-ligase, the von Hippel-Lindau (VHL) protein, which leads to polyubiquitination and rapid proteosomal degradation of HIFa [3,4].”
BackgroundNagaprashantha, L. D., Vatsyayan, R., Singhal, J., Lelsani, P. C. R., Prókai, L., Awasthi, S., & Singhal, S. S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr021 · Cited by 42
Place, T. L., Fitzgerald, M. P., Venkataraman, S., Vorrink, S. U., Case, A. J., Teoh-Fitzgerald, M. L. T., & Domann, F. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014617 · Cited by 50
“Hydroxylated proline residues on HIF-a are recognized by Von HippelLindau (VHL) protein, an E3 ubiquitin ligase that ubiquitinates the HIF-a subunit, targeting it to the proteosome [6].”
Couvé, S., Ladroue, C., Laine, É., Mahtouk, K., Guégan, J., Gad, S., Jeune, H. L., Gentil, M. L., Nuel, G., Kim, W. Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1161 · Cited by 45
Self-citationCAND1 enhances deneddylation of CUL1 by COP9 signalosome
Min, K., Kwon, M., Park, H.-S., Park, Y., Yoon, S. K., & Yoon, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.188 · Cited by 42
Belzutifan: a novel therapeutic for the management of von Hippel–Lindau disease and beyond
Curry, L. C., & Soleimani, M. (2024) · Future Oncology · doi:10.2217/fon-2023-0679 · Cited by 43
Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation
Kim, B.-Y., Kim, H., Cho, E., & Youn, H. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.1.71 · Cited by 43
“Since A498 RCC has no HIF-1α and pVHL can regulate HIF-2α in the similar manner (Maxwell et al., 1999; Ohh et al., 2000; Staller et al., 2003), we detected HIF-2α instead of HIF-1α .”
BackgroundResultInhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule
Welsh, S. J., Dale, A. G., Lombardo, C. M., Valentine, H., de la Fuente, M., Schätzlein, A. G., & Neidle, S. (2013) · Scientific Reports · doi:10.1038/srep02799 · Cited by 42
Activation of Hypoxic Response in Human Embryonic Stem Cell–Derived Embryoid Bodies
Cameron, C. M., Harding, F. J., Hu, W., & Kaufman, D. S. (2008) · Experimental Biology and Medicine · doi:10.3181/0709-rm-263 · Cited by 45
“Under normoxic conditions, HIF-1a is subject to rapid ubiquitination and proteasomal degradation with a half-life of less than 5 minutes (7, 14, 15).”
BackgroundSun, S., Xuan, F., Fu, H., Ge, X., Zhu, J. X., Qiao, H., Jin, S., & Zhang, W. (2016) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2016.02.002 · Cited by 42
Lee, D.-H., Oh, S. C., Giles, A. J., Jung, J., Gilbert, M. R., & Park, D. M. (2017) · Oncotarget · doi:10.18632/oncotarget.16714 · Cited by 41
“Under normoxic conditions, HIF-1α is hydroxylated at Pro-402 and Pro564 residues and is degraded rapidly by ubiquitination and subsequent association with the proteasome system [23, 24].”
BackgroundBailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
“Hippel Lindau (VHL) ubiquitin E3 ligase complex, which targets the transcription factor for rapid proteasome-mediated degradation [6,7].”
BackgroundHypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)
Ban, H. S., Uto, Y., & Nakamura, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874345 · Cited by 44
Involvement of HIF-1 in Invasion of Mum2B Uveal Melanoma Cells
Victor, N., Ivy, A., Jiang, B., & Agani, F. H. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9024-z · Cited by 46
“Central role in the regulation of HIF-1a takes von Hippel-Lindau (VHL) protein, which acts as an ubiquitin-ligase [16, 17] to target HIF-1a for proteasome degradation [18, 19] that is regulated via proline hydroxylation of HIF-1a [20, 21].”
BackgroundProteolysis, the ubiquitin-proteasome system, and renal diseases
Debigaré, R., & Price, S. R. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00244.2002 · Cited by 41
An Essential Role of the HIF‐1α–c‐Myc Axis in Malignant Progression
Yoo, Y., Hayashi, M., Christensen, J., & Huang, L. E. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05043.x · Cited by 40
HAF: The new player in oxygen-independent HIF-1α degradation
Koh, M. Y., & Powis, G. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8303 · Cited by 52
Functional Subunits of Eukaryotic Chaperonin CCT/TRiC in Protein Folding
Kabir, M. A., Uddin, W., Narayanan, A., Reddy, P. K., Jairajpuri, M. A., Sherman, F., & Ahmad, Z. (2011) · Journal of Amino Acids · doi:10.4061/2011/843206 · Cited by 41
“VHL is a subunit of a ubiquitin ligase complex that targets cellular proteins, like HIF-1α, for proteolysis [133, 134].”
BackgroundSaito, Y., Sunamura, M., Motoi, F., Abe, H., Egawa, S., Duda, D. G., Hoshida, T., Fukuyama, S., Hamada, H., & Matsuno, S. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700902 · Cited by 46
Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis
Gläsker, S., Tran, M. G. B., Shively, S. B., Ikejiri, B. L., Lonser, R. R., Maxwell, P. H., Zhuang, Z., Oldfield, E., & Vortmeyer, A. (2006) · The Journal of Pathology · doi:10.1002/path.2029 · Cited by 41
“Mutations within the β-domain of pVHL disrupt its interaction with HIF-α subunits, leading to constitutive HIF-α stabilization and HIF activity [15,16].”
BackgroundXu, Y., Li, Y., Pang, Y., Ling, M., Shen, L., Jiang, R., Zhao, Y., Zhou, J., Wang, X., & Liu, Q. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0810-x · Cited by 40
Lange, C., Heynen, S. R., Tanimoto, N., Thiersch, M., Le, Y.-Z., Meneau, I., Seeliger, M. W., Samardzija, M., Caprara, C., & Grimm, C. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7204 · Cited by 40
HIF-2α phosphorylation by CK1δ promotes erythropoietin secretion in liver cancer cells under hypoxia
Pangou, E., Befani, C., Mylonis, I., Samiotaki, M., Panayotou, G., Simos, G., & Liakos, P. (2016) · Journal of Cell Science · doi:10.1242/jcs.191395 · Cited by 37
“Under normoxia, HIF-2α is modified by the prolyl-4-hydroxylases (PHDs), which then leads to recruitment of the von HippelLindau (VHL) tumor suppressor E3 ligase complex, polyubiquitylation and finally proteasomal degradation (Ohh et al., 2000).”
BackgroundRedox regulation of ischemic limb neovascularization – What we have learned from animal studies
Matsui, R., Watanabe, Y., & Murdoch, C. E. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.040 · Cited by 40
“Under hypoxia, PHD activity and subsequent HIF-1α hydroxylation are attenuated, resulting in less degradation and accumulation of HIF-1α.”
BackgroundHypoxia-Inducible Factor (HIF): Fuel for Cancer Progression
Satija, S., Kaur, H., Tambuwala, M. M., Sharma, P., Vyas, M., Khurana, N., Sharma, N., Bakshi, H. A., Charbe, N. B., Zacconi, F. C. M., et al. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210120154929 · Cited by 40
Ubiquitin-dependent regulation of transcription in development and disease
Mark, K. G., & Rapé, M. (2021) · EMBO Reports · doi:10.15252/embr.202051078 · Cited by 41
“Accordingly, transcription factors responding to hypoxia (HIF1 a ), oxidative stress (NRF2), or DNA damage (TP53), are constantly turned over under homeostatic conditions, yet instantly stabilized upon stress (Salceda & Caro, 1997; Giaccia & Kastan, 1998; Ohh et al, 2000; Ma, 2013).”
CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14ARF degradation
Zhang, P., Gao, K., Zhang, L., Sun, H., Zhao, X., Liu, Y., Lv, Z., Shi, Q., Chen, Y., Jiao, D., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00890-0 · Cited by 41
Hypoxia inducible factor 1α inhibitor PX-478 reduces atherosclerosis in mice
Villa-Roel, N., Ryu, K., Gu, L., Fernandez Esmerats, J., Kang, D.-W., Kumar, S., & Jo, H. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.002 · Cited by 38
Oxygen and Cell Fate Decisions
Lin, Q., Kim, Y., Alarcon, R. M., & Yun, Z. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s434 · Cited by 46
“…HIF-1α protein becomes hydroxylated at two proline residues located in its O2-dependent degradation domain (Ivan et al. 2001; Jaakkola et al. 2001) and is targeted by the von Hippel-Lindau (VHL) protein for ubiquitination and proteosome-mediated degradation (Maxwell et al. 1999; Ohh et al. 2000).”
Mettu, P., Agrón, E., Samtani, S., Chew, E. Y., & Wong, W. T. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5223 · Cited by 40
Kinase inhibitors in the treatment of renal cell carcinoma
Larkin, J., & Eisen, T. G. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.008 · Cited by 43
Gerber, M., Eissenberg, J. C., Kong, S. E., Tenney, K., Conaway, J. W., Conaway, R., & Shilatifard, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9911-9919.2004 · Cited by 40
Tzouanacou, E., Tweedie, S., & Wilson, V. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8553-8562.2003 · Cited by 40
Mammalian target of rapamycin (mTOR) inhibitors
Dutcher, J. P. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0022-5 · Cited by 41
Haddad, J. J. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.06.006 · Cited by 42
What influences the activity of Degrader−Antibody conjugates (DACs)
Guo, Y., Li, X., Xie, Y., & Wang, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116216 · Cited by 40
The von Hippel-Lindau Tumor Suppressor Protein Is a Molten Globule under Native Conditions
Sutovsky, H., & Gazit, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311225200 · Cited by 44
Dey, P., Velázquez‐Villegas, L. A., Faria, M., Turner, A. P. F., Jonsson, P., Webb, P., Williams, C., Gustafsson, J.-Å., & Ström, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128239 · Cited by 41
“Prolyl hydroxylation causes HIF-1α to interact with the Von Hippel Lindau factor (VHL), leading to ubiquitination and degradation of HIF-1α by the proteasome complex [18–21].”
BackgroundHypoxia and viral infectious diseases
Huang, R., Huestis, M., Gan, E. S., Ooi, E. E., & Ohh, M. (2021) · JCI Insight · doi:10.1172/jci.insight.147190 · Cited by 41
Self-citationGuo, K., Wei, Y., Wang, Z., Zhang, X., Zhang, X., Liu, X., Wu, W., Wu, Z., Zhang, L., & Cui, C. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04135-3 · Cited by 45
Elucidating the role of hypoxia-inducible factor in rheumatoid arthritis
Sabi, E. M., Singh, A., Althafar, Z. M., Behl, T., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., Alqahtani, H. M., et al. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00974-4 · Cited by 43
“HIF-2 is typically upregulated in fibroblasts affecting the cellular proliferation, NF-kB ligand production signaling cascades, and catabolic factor activation (Ohh et al. 2000).”
BackgroundHIF-1 : régulateur central de l’hypoxie
Gothié, E., & Pouysségur, J. (2002) · médecine/sciences · doi:10.1051/medsci/200218170 · Cited by 44
Tran, T. A. T., Leong, H. S., Pavía-Jiménez, A., Fedyshyn, S., Yang, J., Kucejová, B., Sivanand, S., Spence, P., Xie, X., Peña‐Llopis, S., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00189-16 · Cited by 40
Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism
Meisel, J. D., Miranda, M., Skinner, O. S., Wiesenthal, P. P., Wellner, S. M., Jourdain, A. A., Ruvkun, G., & Mootha, V. K. (2024) · Cell · doi:10.1016/j.cell.2023.12.010 · Cited by 39
Choi, S. H., Jee, B. Y., Lee, S. J., Cho, M. Y., Lee, S. J., Kim, J. W., Jeong, H. D., & Kim, K. H. (2013) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2013.05.001 · Cited by 40
U19/Eaf2 Binds to and Stabilizes von Hippel-Lindau Protein
Xiao, W., Ai, J., Habermacher, G. M., Volpert, O. V., Yang, X. J., Zhang, A.-Y., Hahn, J., Cai, X., & Wang, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2595 · Cited by 39
“pVHL contributes to the regulation of oxygen-responsive gene expression by targeting the transcription factor hypoxia-inducible factor 1a (HIF1a) for proteasomal degradation under normoxic conditions (8, 9).”
Murray, J. K., Chenera, B., Allgeier, A. M., Kasparian, A. J., Viswanadhan, V. N., Wilde, C., Allen, J. R., Yoder, S. C., Biddlecome, G. H., Hungate, R. W., et al. (2010) · Journal of Combinatorial Chemistry · doi:10.1021/cc100073a · Cited by 44
Expression and stability of hypoxia inducible factor 1α in osteosarcoma
El-Naggar, A. M., Clarkson, P. W., Zhang, F., Mathers, J. A., Tognon, C. E., & Sorensen, P. H. B. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24191 · Cited by 39
HIF-1α modulates sex-specific Th17/Treg responses during hepatic amoebiasis
Groneberg, M., Hoenow, S., Marggraff, C., Fehling, H., Metwally, N. G., Hansen, C. S., Bruchhaus, I., Tiegs, G., Sellau, J., & Lotter, H. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.020 · Cited by 40
Endothelial cell KIT expression in human tumours
Sihto, H. J., Tynninen, O., Bützow, R. C., Saarialho‐Kere, U., & Joensuu, H. (2007) · The Journal of Pathology · doi:10.1002/path.2125 · Cited by 38
“Tissue hypoxia induces expression not only of VEGF, but also of many other genes presumably associated with angiogenesis and with the maintenance of tissue oxygen levels [16,17].”
BackgroundTang, Y.-Q., Han, B.-M., Yao, X.-Q., Hong, Y., Wang, Y., Zhao, F.-J., Yu, S.-Q., Sun, X.-W., & Xia, S.-J. (2009) · Asian Journal of Andrology · doi:10.1038/aja.2008.26 · Cited by 35
Aggelis, V., Craven, R. A., Peng, J., Harnden, P., Cairns, D. A., Maher, E. R., Tonge, R., Selby, P. J., & Banks, R. E. (2009) · PROTEOMICS · doi:10.1002/pmic.200800756 · Cited by 38
“The most extensively documented function of VHL is its role as the substrate recognition component of an E3 multi-subunit ubiquitin ligase formed with elongins B and C, Cul-2 and Rbx1 that targets hypoxia-inducible factor (HIF)-a for polyubiquitination and subsequent proteasomal degradation in an oxygen-dependent fash…”
BackgroundLeu-574 of HIF-1α Is Essential for the von Hippel-Lindau (VHL)-mediated Degradation Pathway
Huang, L. E., Pete, E. A., Schau, M., Milligan, J., & Gu, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207280200 · Cited by 37
Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter
Zatyka, M., Morrissey, C., Kuzmin, I., Lerman, M. I., Latif, F., Richards, F. M., & Maher, E. R. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.463 · Cited by 40
Von Hippel-Lindau disease: gene to bedside
Sims, K. B. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200112000-00004 · Cited by 38
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Shirole, N. H., & Kaelin, W. G. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.04.011 · Cited by 39
Self-citationLee, P. W. T., Koseki, L. R., Haitani, T., Harada, H., & Kobayashi, M. (2024) · Cancers · doi:10.3390/cancers16091729 · Cited by 42
Shieh, T., Chang, K., Tu, H., Shih, Y.-H., Ko, S.-Y., Chen, Y.-C., & Liu, C. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.04.009 · Cited by 38
Huang, Y., Ochieng, J. K., Kempen, M. B., Munck, A. B., Swagemakers, S. M. A., van IJcken, W. F. J., Grosveld, F. G., Tibboel, D., & Rottier, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057695 · Cited by 47
“The hydroxylated HIFa proteins are poly-ubiquitinylated and targeted for 26S proteosomal degradation through the von Hippel-Lindau (pVHL)/Elongin BC/Cul2 ubiquitin-ligase complex [28,29,30,31,32,33,34].”
BackgroundDimova, E., Michiels, C., & Kietzmann, T. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649358 · Cited by 37
“Hydroxylation of the proline residues within the ODDD allows binding of the von HippelLindau tumor suppressor protein (pVHL) as part of an E3 ubiquitin ligase complex which subsequently leads to ubiquitination and proteasome-dependent degradation of HIF-1 [20-27].”
BackgroundSato, T., Kawasaki, Y., Maekawa, M., Takasaki, S., Saigusa, D., Ota, H., Shimada, S., Yamashita, S., Mitsuzuka, K., Yamaguchi, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32115 · Cited by 37
c-Met expression in renal cell carcinoma with bone metastases
Paiva, R. S., Gomes, I., Casimiro, S., Fernandes, I., & Costa, L. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100315 · Cited by 37
Henríquez, J. A., Sleeman, J. P., & Garvalov, B. K. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9930-x · Cited by 39
Hipoxia tumoral. Papel del factor inducible por hipoxia
Fraga, A. M., Ribeiro, R. J. T., & Medeiros, R. (2009) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(09)72891-8 · Cited by 50
Vaux, E. C., Wood, S. M., Cockman, M. E., Nicholls, L. G., Yeates, K. M., Pugh, C. W., Maxwell, P. H., & Ratcliffe, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104678200 · Cited by 37
Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling
Heir, P., Srikumar, T., Bikopoulos, G. J., Bunda, S., Poon, B., Lee, J. E., Raught, B., & Ohh, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694562 · Cited by 36
“786-O lines stably expressing HAVHL or empty plasmid were previously described (3, 4).”
BackgroundMethodSelf-citationHypoxia-Inducible Factors: Post-translational Crosstalk of Signaling Pathways
Dimova, E. Y., & Kietzmann, T. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-738-9_13 · Cited by 37
VEGF inhibitors in renal cell carcinoma.
Vachhani, P. J., & George, S. (2016) · PubMed · Cited by 36
VBP 1 represses cancer metastasis by enhancing HIF ‐1α degradation induced by pVHL
Kim, J. A., Choi, D. K., Min, J. S., Kang, I., Kim, J. C., Kim, S., & Ahn, J. K. (2017) · FEBS Journal · doi:10.1111/febs.14322 · Cited by 39
Basic, V., Roxlau, E. T., Elmabsout, A. A., Yao, H., Rahman, I., Sirsjö, A., & Abdel‐Halim, S. M. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00007.2012 · Cited by 37
“UBE2D1-conjugating enzyme to lysil residues of HIF-1 protein marking it for rapid proteosomal degradation (18, 21, 33, 36).”
BackgroundMgcRacGAP Interacts with HIF-1α and Regulates its Transcriptional Activity
Lyberopoulou, A., Venieris, E., Mylonis, I., Chachami, G., Pappas, I., Simos, G., Bonanou, S., & Georgatsou, E. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110460 · Cited by 36
Negative regulation of hypoxia inducible factor‐1α by necdin
Moon, H.-E., Ahn, M.-Y., Park, J. A., Min, K., Kwon, Y., & Kim, K.-W. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.072 · Cited by 42
“Under normoxia, HIF-1a is rapidly degraded by the ubiquitin-proteasome pathway [7,12,13].”
BackgroundLam, J. S., Pantuck, A. J., Belldegrun, A. S., & Figlin, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1864 · Cited by 36
Playing Tag with HIF: The VHL Story
Leung, S. K., & Ohh, M. (2002) · BioMed Research International · doi:10.1155/s1110724302205057 · Cited by 44
“Intriguingly, the ODD domain of HIFα subunit is both necessary and sufficient for binding to pVHL [21, 22, 23].”
BackgroundSelf-citationOverexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1α eradicates gliomas
Sun, X., Liu, M., Wei, Y., Liu, F., Zhi, X., Xu, R., & Krissansen, G. W. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700907 · Cited by 41
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.